Completed PHASE3 INTERVENTIONAL 3-arm NCT00594568

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo

Sponsor: Eli Lilly and Company

Updated 8 times since 2017 Last updated: Mar 13, 2015 Started: Mar 31, 2008 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer's Disease, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Adelaide, Australia , Albacete, Spain , Albany, United States , Antofagasta, Chile , Antwerp, Belgium , Ashkelon, Israel , Baltimore, United States , Barakaldo, Spain , Barcelona, Spain and 137 more locations